{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:07:08Z","timestamp":1779217628720,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102171","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:36:47Z","timestamp":1721767007000},"page":"102171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale"],"prefix":"10.1016","volume":"22","author":[{"given":"Cora N.","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102171_bib0001","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program. SEER*stat database: incidence - SEER research data, 8 registries, Nov 2021 Sub (1975-2020) - linked to county attributes - time dependent (1990-2020) income\/rurality, 1969-2020 counties. Available from www.seer.cancer.gov. Accessed May 16, 2024."},{"key":"10.1016\/j.clgc.2024.102171_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2024.102171_bib0003","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above","volume":"95","author":"Kupelian","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102171_bib0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2024.102171_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0006","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2024.102171_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659135","article-title":"Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies","volume":"11","author":"Wenzel","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0008","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0009","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0010","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0012","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0014","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clgc.2024.102171_bib0017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2024.102171_bib0018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0019","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer V.4.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2023. Accessed June 16, 2024."},{"key":"10.1016\/j.clgc.2024.102171_bib0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0021","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.3390\/cancers13194982","article-title":"Oligometastatic disease detection with (68)Ga-PSMA-11 PET\/CT in hormone-sensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact","volume":"13","author":"Artigas","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2024.102171_bib0022","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0023","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0024","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0026","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"10","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0027","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0028","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0031","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2021.39.15_suppl.5068","volume":"39","author":"Agarwal","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0032","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0033","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0034","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2024.102171_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0037","doi-asserted-by":"crossref","first-page":"LBA5004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5004","article-title":"Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Davis","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0036","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102171_bib0038","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.clgc.2024.102171_sbref0039","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1002\/cam4.4372","article-title":"Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration","volume":"10","author":"Freedland","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.clgc.2024.102171_bib0040","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2024.102171_bib0041","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2021.39.15_suppl.5074","article-title":"Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings","volume":"39","author":"George","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0042","doi-asserted-by":"crossref","first-page":"pkab082","DOI":"10.1093\/jncics\/pkab082","article-title":"Real-world use of androgen-deprivation therapy: intensification among older canadian men with de novo metastatic prostate cancer","volume":"5","author":"Wallis","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.clgc.2024.102171_bib0043","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0044","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1200\/JCO.2022.40.16_suppl.5065","article-title":"Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): a physician survey linked to patient chart reviews in the United States","volume":"40","author":"Freedland","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0045","doi-asserted-by":"crossref","first-page":"13247","DOI":"10.2147\/OTT.S242921","article-title":"A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research","volume":"13","author":"Laccetti","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clgc.2024.102171_bib0046","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14740338.2021.1919620","article-title":"A drug safety evaluation of enzalutamide to treat advanced prostate cancer","volume":"20","author":"Saad","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clgc.2024.102171_bib0047","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102171_bib0048","doi-asserted-by":"crossref","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2024.102171_bib0049","doi-asserted-by":"crossref","first-page":"TPS5090","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5090","article-title":"A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19)","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0050","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2018.36.15_suppl.5002","article-title":"A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone na\u00efve prostate cancer (M0HNPC)","volume":"36","author":"Efstathiou","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046588","article-title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","volume":"11","author":"Freedland","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.clgc.2024.102171_bib0052","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102171_bib0053","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0054","doi-asserted-by":"crossref","first-page":"TPS254","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS254","article-title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)","volume":"42","author":"Chehrazi-Raffle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0055","first-page":"e28","volume":"211","author":"Agarwal","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0056","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0057","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2024.102171_bib0058","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.2013.8638","article-title":"Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer","volume":"310","author":"Lapi","year":"2013","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.clgc.2024.102171_bib0059","first-page":"S35","article-title":"Hormonal therapy for prostate cancer","volume":"8","author":"Brawer","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2024.102171_bib0061","first-page":"303","article-title":"Complications of androgen deprivation therapy: prevention and treatment","volume":"18","author":"Holzbeierlein","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clgc.2024.102171_bib0062","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/annonc\/mdr447","article-title":"Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy","volume":"23","author":"Storey","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0063","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2024.102171_bib0064","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102171_bib0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0066","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0067","unstructured":"Astellas Pharma US, Inc. XTANDI\u24c7 (enzalutamide) capsules, for oral use. https:\/\/www.astellas.us\/docs\/12A005-ENZ-WPI.PDF. Northbook, IL: Astellas Pharma; 2023. Accessed: 10\/06\/2024."},{"key":"10.1016\/j.clgc.2024.102171_bib0068","unstructured":"EMA. Xtandi. 2024. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi. Accessed: 05\/08\/2024."},{"key":"10.1016\/j.clgc.2024.102171_bib0069","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102171_bib0070","doi-asserted-by":"crossref","first-page":"e1191","DOI":"10.1097\/JU.0000000000003361.11","article-title":"LBA02-11 updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)","volume":"209","author":"Aggarwal","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0071","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.06.017","article-title":"Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na\u00efve prostate cancer","volume":"157","author":"Spetsieris","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2024.102171_bib0072","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1464-410X.2011.10728.x","article-title":"Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes","volume":"110","author":"Mazzola","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2024.102171_bib0073","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102171_bib0074","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","article-title":"Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis","volume":"93","author":"Shahani","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2024.102171_bib0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41391-022-00519-4","article-title":"A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)","volume":"25","author":"Harrison","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2024.102171_bib0076","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-021-00481-7","article-title":"Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients","volume":"25","author":"Rivera-Izquierdo","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2024.102171_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164169","article-title":"Obesity as a risk factor for prostate cancer mortality: a systematic review and dose-response meta-analysis of 280,199 patients","volume":"13","author":"Rivera-Izquierdo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2024.102171_bib0078","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-19-3873","article-title":"A randomized controlled trial of a 6-month low-carbohydrate intervention on disease progression in men with recurrent prostate cancer: carbohydrate and prostate study 2 (CAPS2)","volume":"26","author":"Freedland","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102171_bib0079","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41391-023-00711-0","article-title":"Application of next-generation imaging in biochemically recurrent prostate cancer","volume":"27","author":"Moul","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:31:31Z","timestamp":1762551091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001423"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102171","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102171"}}